A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2018-11-16
Target enrollment:
Participant gender:
Summary
Fruquintinib/Placebo 5 mg, QD, orally administered under fasting conditions for 3 consecutive
weeks followed by one-week off to evaluate the survival benefit of patients with advanced
non-squamous NSCLC treated with Fruquintinib.
Phase:
Phase 3
Details
Lead Sponsor:
Hutchison Medipharma Limited
Collaborators:
Affiliated Hospital to Academy of Military Medical Sciences Beijing Cancer Hospital Beijing Chest Hospital First Affiliated Hospital of Zhejiang University First Hospital of Jilin University Fudan University Guangdong General Hospital Harbin Medical University Health Science Center of Xi’an Jiaotong University Jilin Provincial Tumor Hospital Linyi Tumour Hospital Quintiles, Inc. Shanghai Chest Hospital Sir Run Run Shaw Hospital The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China The First Affiliated Hospital of Guangzhou Medical University West China Hospital Xinjiang Medical University